Last reviewed · How we verify
NCT03206827: ScenoProt
Effect of Plant and Animal Proteins on Biomarkers of Colorectal Cancer and Type 2 Diabetes in Healthy Adults (ScenoProt)
NA trial testing 70% animal, 30% plant proteins in diet in Colorectal Cancer in 147 participants. Completed in 24 September 2021.
30 June 2017
Quick facts
| Lead sponsor | University of Helsinki |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 147 |
| Start date | 29 November 2016 |
| Primary completion | 30 June 2017 |
| Estimated completion | 24 September 2021 |
Drugs / interventions tested
- 70% animal, 30% plant proteins in diet
- 50% animal, 50% plant proteins in diet
- 30% animal, 70% plant proteins in diet
Conditions studied
- Colorectal Cancer — all drugs for Colorectal Cancer →
- Type2 Diabetes — all drugs for Type2 Diabetes →
Sponsor
University of Helsinki
Who can join
Adults 20 to 69, any sex, with Colorectal Cancer or Type2 Diabetes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to investigate the effects of dietary plant and animal proteins on gut metabolism and markers for colorectal cancer as well as blood protein metabolites and markers for type 2 diabetes in healthy adults. The study participants will be stratified into three groups with different protein composition in diets: 1) animal 70%/plant 30%; 2) animal 50%/plant 50% and 3) animal 30%/plant 70%. The participants will get part of their diet as ready foods or raw material to promote their compliance. The participants will also get personal advice for their diets. Blood, stool and urine samples will be collected in the beginning and in the end of the 12 week intervention, as well as phenotype measures like BMI, blood pressure and body composition. The participants will also fill food diary before and in the end of the intervention.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Replacing Animal-Based Proteins with Plant-Based Proteins Changes the Composition of a Whole Nordic Diet-A Randomised Clinical Trial in Healthy Finnish Adults.
Päivärinta E, Itkonen ST, Pellinen T, Lehtovirta M, et al · · 2020 · cited 61× · PMID 32231103 · DOI 10.3390/nu12040943 -
Replacing dietary animal-source proteins with plant-source proteins changes dietary intake and status of vitamins and minerals in healthy adults: a 12-week randomized controlled trial.
Pellinen T, Päivärinta E, Isotalo J, Lehtovirta M, et al · · 2022 · cited 35× · PMID 34837522 · DOI 10.1007/s00394-021-02729-3 -
Partial Replacement of Animal Proteins with Plant Proteins for 12 Weeks Accelerates Bone Turnover Among Healthy Adults: A Randomized Clinical Trial.
Itkonen ST, Päivärinta E, Pellinen T, Viitakangas H, et al · · 2021 · cited 32× · PMID 32939557 · DOI 10.1093/jn/nxaa264 -
Dietary climate impact correlates ambiguously with health biomarkers- a randomised controlled trial in healthy Finnish adults.
Saarinen M, Pellinen T, Kostensalo J, Nousiainen J, et al · · 2025 · cited 4× · PMID 39964546 · DOI 10.1007/s00394-025-03609-w -
Identifying gaps between perceived and actual intakes in Finnish adults: self-assessment of macronutrient intakes in relation to nutrition recommendations is challenging.
Bäck S, Pellinen T, Päivärinta E, Rautio P, et al · · 2025 · PMID 41079687 · DOI 10.29219/fnr.v69.10535
Verify or expand the search:
- PubMed search for NCT03206827
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Colorectal Cancer
Currently open trials in the same condition.
- NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
- NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
- NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting
Other University of Helsinki trials
Trials by the same sponsor.
- NCT07212361 — Infant Microbiota Restoration With Maternal Microbes · NA · recruiting
- NCT06799988 — NutFinForce: The Impact of Digitally Delivered Lifestyle Performance Medicine Intervention on Defense Performance in Fin · not yet recruiting
- NCT06464003 — Orthodontic Screening in Public Healthcare · recruiting
- NCT06092372 — The Role of Genetics in Weight Loss · NA · completed
- NCT06564675 — Accuracy of EEG Slow Wave Activity in Predicting Favourable Outcome in Patients With Hypoxic Brain Injury - A Substudy o · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03206827 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Helsinki
- Last refreshed: 27 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03206827.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing